---
schema_version: "secwatch.filing_event.v1"
accession: "0001140361-23-014662"
form_type: "8-K"
ticker: "FEMY"
cik: "0001339005"
company_name: "FEMASYS INC"
filed_at: "2023-03-30T23:59:59+00:00"
generated_at: "2026-06-17T09:03:23.872854+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Femasys reports 2022 net loss of $11.4M, revenue up 2.2% to $1.2M

## Summary
- Net loss of $11.4M ($0.96 per share) vs $7.5M loss in 2021; cash $12.96M expected to fund into Q1 2024.
- Revenue $1.21M (+2.2% YoY); gross margin fell to 63.4% from 68.6%.
- R&D expenses rose 42% to $5.81M; G&A expenses rose 27% to $5.43M.
- Commercial launches of FemCath (tubal evaluation) and FemCerv (tissue sampler) in late 2022.
- Clinical progress: FemBloc Stage 2 enrollment complete; FemaSeed pivotal trial 25% enrolled.

## SEC filing metadata
- accession: 0001140361-23-014662
- form_type: 8-K
- ticker: FEMY
- cik: 0001339005
- company_name: FEMASYS INC
- filed_at: 2023-03-30T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 5.03, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1339005/000114036123014662/0001140361-23-014662-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1339005/000114036123014662/brhc10050619_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001140361-23-014662
- JSON: https://secwatch.observer/filing/0001140361-23-014662.json
- Plain text: https://secwatch.observer/filing/0001140361-23-014662.txt

## Key facts
- Earnings Releases
  FEMASYS INC reported financial results for year ended December 31, 2022.
  - Period: year ended December 31, 2022
  - Result: reported results
  source text: On March 30, 2023, Femasys Inc. announced its financial results for the year ended December 31, 2022.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1339005/000114036123014662/0001140361-23-014662-index.htm
- Governance Changes
  FEMASYS INC: Reduced stockholder meeting quorum requirement to 33.4% (effective 2023-03-29).
  - Change: bylaw amendment
  - Effective: 2023-03-29
  source text: On March 29, 2023, the Board of Directors of Femasys Inc. amended Section 5 of Article I of Femasys Inc.’s Amended and Restated Bylaws to reduce the quorum requirement for any meeting of stockholders to 33.4%.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1339005/000114036123014662/0001140361-23-014662-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.